Treatment of Metastatic Breast Carcinoma Refactory to Doxorubicin with Liposomal-Annamycin
Annual rept. 23 Sep 1998-22 Sep 1999
M D ANDERSON CANCER CENTER HOUSTON TX
Pagination or Media Count:
Fourteen patients with metastatic breast carcinoma refractory to doxorubicin were entered in a Phase II study of liposomal-annamycin, a new anthracycline antibiotic which has shown ability to circumvent multidrug resistance. A total of 25 doses of liposomal- annamycin were given at three different dose levels. Toxicity was mild and limited to granulocytopenia in less than 50 of patients. No antitumor responses were seen.
- Medicine and Medical Research